Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20336332 | 0.88 | ALDH1A1 (0.49) | ALDH1A1PKMKDM4ELMNAMEN1 | |
| SCHEMBL12750055 | 0.83 | ALDH1A1 (0.43) | ALDH1A1PKMKDM4ELMNAMEN1 | |
| SCHEMBL10104439 | 0.83 | ALDH1A1 (0.43) | ALDH1A1PKMKDM4ELMNAMEN1 | |
| SCHEMBL10348129 | 0.81 | ALDH1A1 (0.42) | ALDH1A1PKMKDM4ELMNAMEN1 | |
| SCHEMBL18587118 | 0.80 | ALDH1A1 (0.42) | ALDH1A1PKMKDM4ELMNAMEN1 | |
| SCHEMBL21894119 | 0.79 | KCNN4 (0.50) | ALDH1A1KDM4ELMNAMEN1GAA | |
| SCHEMBL18608785 | 0.78 | ALDH1A1 (0.42) | ALDH1A1PKMKDM4ELMNAMEN1 | |
| SCHEMBL17141721 | 0.78 | MEN1 (0.59) | ALDH1A1PKMKDM4ELMNAMEN1 | |
| SCHEMBL9945328 | 0.78 | ALDH1A1 (0.57) | ALDH1A1PKMKDM4ELMNAHCRTR1 | |
| SCHEMBL1956156 | 0.78 | ALDH1A1 (0.42) | ALDH1A1PKMKDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| EP-3966196-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3800183-A1 | UREA DERIVATIVES AS TRK-INHIBITING COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2021-04-07 | — | — | EP | disclosed |
| EP-3459935-B1 | UREA DERIVATIVE AS TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020225569-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2020-11-12 | — | — | WO | disclosed |
| US-10765676-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-08 | — | — | US | disclosed |
| US-10399959-B2 | Acid-addition salt of Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-01 | — | — | US | disclosed |
| CN-101273027-A | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARM LTD (IE) | 2008-09-24 | — | — | CN | disclosed |
| EP-1919898-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | ALDH1A1 1477/4885PKM 4666/4885KDM4E 1036/4885 |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | ERAP1, CHP1, QSOX1 | ALDH1A1 1546/4885PKM 4579/4885KDM4E 1040/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | ALDH1A1 1431/4885PKM 4631/4885KDM4E 1035/4885 |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | ALDH1A1 2491/4885PKM 1771/4885KDM4E 2556/4885 |
| US-10765676-B2 | Trk-inhibiting compound | LTK, ROR1, TRPV1 | ALDH1A1 2491/4885PKM 1771/4885KDM4E 2556/4885 |
| US-10399959-B2 | Acid-addition salt of Trk-inhibiting compound | NTRK1, NGF, NTRK2 | ALDH1A1 2939/4885PKM 2250/4885KDM4E 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.